Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Korean Patients With Active Rheumatoid Arthritis
NCT00202852Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Primary completion
- Mar 2006
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in rheumatoid arthritis (RA), sponsored by Merck & Co.. Started Jun 2005; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00202852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202852.